Verifying…
Home / Drug A–Z / Ibu Pharm Lisinopril Tablets USP 10 mg

Ibu Pharm Lisinopril Tablets USP 10 mg

NAFDAC Reg. No. B4-9581 · Drug

Registered with NAFDAC. Registration activeAs of 27 October 2026 · synced automatically from official sources.
Product
Ibu Pharm Lisinopril Tablets USP 10 mg
NAFDAC number
B4-9581
Active ingredient
Lisinopril
Strength
10 mg
Form
Tablet
Pack size
2 x 14's (in blisters)
Manufacturer
Not listed
Applicant (holder)
Ibu Pharm Nig Ltd
Approved
26 Nov 2025
Status
Active View on NAFDAC ↗
Registration valid to
25 Nov 2030
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Ibu Pharm Lisinopril Tablets USP 10 mg is on the NAFDAC register with an active registration (B4-9581). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

What Ibu Pharm Lisinopril Tablets USP 10 mg is used for

From the official U.S. FDA label for lisinopril, the active ingredient registered with NAFDAC.

Boxed warning: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue lisinopril as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 ) WARNING: FETAL TOXICITY When pregnancy is detected, discontinue lisinopril as soon as possible [see WARNINGS AND PRECAUTIONS ( 5.1 )] . …
What it is used for

Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. …

Possible side effects

Common adverse reactions (events 2% greater than placebo) by use: Hypertension: headache, dizziness and cough ( 6.1 ) Heart Failure: hypotension and chest pain ( 6.1 ) Acute Myocardial Infarction: hypotension ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. …

Do not use if

Angioedema or a history of hereditary or idiopathic angioedema ( 4 ) Hypersensitivity ( 4 ) Co-administration of aliskiren with lisinopril in patients with diabetes ( 4 , 7.4 ) Lisinopril is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer Lisinopril tablet USP within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see WARNINGS and PRECAUTIONS ( 5.2 )]. …

Warnings

Angioedema: Discontinue lisinopril, provide appropriate therapy and monitor until resolved ( 5.2 ) Renal impairment: Monitor renal function periodically ( 5.3 ) Hypotension: Patients with other heart or renal diseases have increased risk, monitor blood pressure after initiation ( 5.4) Hyperkalemia: Monitor serum potassium periodically ( 5.5 ) Cholestatic jaundice and hepatic failure: Monitor for jaundice or signs of liver failure ( 5.6 ) 5.1 Fetal Toxicity Lisinopril can cause fetal harm when administered to a pregnant woman. …

Pregnancy & breastfeeding

8.1 Pregnancy Risk Summary Lisinopril can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. …

General information only, not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

NAFDAC recall & alert notices

Public Alert No. 31/2026- Recall of Sexual Enhancement Product Due to Undeclared Pharmaceutical Ingredients18 Jun 2026 · nafdac.gov.ngThe National Agency for Food and Drug Administration and Control (NAFDAC) received a notification that Best Supplements Best Prices Company is voluntarily recalling all lots of WAP Sensual Enhancement capsules to the consumer level following the detection of undeclared pharmaceutical ingredients by the U.S Food and Dru…Public Alert No. 040/2025 – Mop up of all Products Produced and Distributed by EuroPharm Laboratories2 Dec 2025 · nafdac.gov.ngThe National Agency for Food and Drugs Administration and Control (NAFDAC) is informing the healthcare providers and the general public of the nationwide mop up of all products produced and distributed by EUROPHARM LABORATORIES.NAFDAC commenced this enforcement actions against Europharm Laboratories, following credible…Public Alert No. 35/2025 – Substandard batches of Annmox (Amoxicillin suspensions 125mg/5ml) and Jawamox (Amoxicillin suspension 125mg/5ml) manufactured by Jawa International Ltd due to low Active Pharmaceutical Ingredient (API) content22 Oct 2025 · nafdac.gov.ngThe National Agency for Food and Drugs Administration and Control (NAFDAC) is notifying the public about the mop up of batches of confirmed substandard Annmox (Batch 360M) and Jawamox (Batch 4231M & 4290M) Suspensions.The products failed laboratory analysis due to low Active Pharmaceutical Ingredient (API) content.The …Public Alert No. 024/2025 – Recall of Amoxivue (Amoxicillin) 500mg Capsules due to significantly low Active Pharmaceutical Ingredient (API) content6 Aug 2025 · nafdac.gov.ngThe National Agency for Food and Drug Administration and Control (NAFDAC) is alerting the public about the recall of Amoxivue (Amoxicillin) 500mg, with NAFDAC NO: A4-100178 and Batch NO: 322584, manufactured by Sparsh Bio-Tech Pvt, Ltd.Note: Sparsh Bio-Tech has declared no relationship with the MAH- MedVue Pharmaceutic…

Compare the brands and batch numbers in these notices with your pack, or enter your batch number above.

Check your pack of Ibu Pharm Lisinopril Tablets USP 10 mg

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Ibu Pharm Lisinopril Tablets USP 10 mg

What is in Ibu Pharm Lisinopril Tablets USP 10 mg?

Ibu Pharm Lisinopril Tablets USP 10 mg contains Lisinopril (10 mg), as tablet, according to its NAFDAC registration record.

Is Ibu Pharm Lisinopril Tablets USP 10 mg registered with NAFDAC?

Yes. Ibu Pharm Lisinopril Tablets USP 10 mg is listed on the NAFDAC register under registration number B4-9581, and its registration is active as of 27 October 2026.

Has Ibu Pharm Lisinopril Tablets USP 10 mg been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Ibu Pharm Lisinopril Tablets USP 10 mg in our automatically synced alert list.

How can I check that my pack of Ibu Pharm Lisinopril Tablets USP 10 mg is genuine?

Run a free authenticity scan with the NAFDAC number B4-9581, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Ibu Pharm Lisinopril Tablets USP 10 mg used for?

Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 (Summarised from the official U.S. FDA label for lisinopril. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Ibu Pharm Lisinopril Tablets USP 10 mg? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.